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Abstract
Introduction PCA3 is a non-coding mRNA molecule that
is overexpressed in prostate cancer. The purpose of this
study is to evaluate the utility of the PCA3 molecular urine
test scores to predict adverse pathologic features and
catheterized specimen collection.
Methods Hundred men with clinically localized prostate
cancer scheduled to undergo robotic prostatectomy were
enrolled in the study following a standard consent process.
The study protocol consisted of providing four urine
samples. Voided urine obtained following digital rectal
examination (DRE) pre-operatively (Vl), catheterized urine
without DRE (V2), and l0-day and 6-week postoperative
voided (V3 and V4) urine samples were collected and
analyzed. These four urine specimens underwent target
capture, transcription-mediated ampliﬁcation, and hybrid-
ization in order to quantify both PCA3 and PSA mRNA.
The PCA3 score was calculated as the ratio of PCA3 to
PSA.
Results Informative rates (sufﬁcient mRNA for analysis)
for VI, V2, V3 and V4 were 91, 85, 0 and 2%, respectively.
There was no signiﬁcant associations with pathological
stage, Gleason score [6. Higher PCA3 scores at V1
correlated with increased risk for perineural invasion
(P = 0.0479).
Conclusions Informative PCA3 scores can be obtained
from post-DRE voided urine as well as catheterized urine
without a DRE. The PCA3 test does not seem to predict
adverse pathologic features, though, may have an associ-
ation with perineural invasion. The ability of PCA3 score
to predict clinical outcome remains to be determined.
Keywords Prostate cancer  Tumor marker  Diagnosis 
Prostate-speciﬁc antigen  Biological  Gene expression
Introduction
Prostate cancer is the second leading cause of cancer-
related deaths among men in the United States [1].
Although still controversial, there is growing evidence that
early detection will reduce prostate cancer mortality [2, 3].
Currently, the gold standard to aid in early prostate cancer
detection is measurement of serum prostate-speciﬁc anti-
gen (PSA) levels. Despite the value of PSA, it has some
limitations in regard to both sensitivity and speciﬁcity since
serum PSA can be elevated from benign conditions such as
prostatitis and benign prostatic hyperplasia, and clinically
relevant prostate cancer can exist in men with very low
PSA levels (i.e.,\2.5 ng/ml) [4, 5]. The PCA3 molecular
urine test is a new biomarker utilizes the detection of
DD3
PCA3 mRNA in prostate cells in urine for detection of
prostate cancer, and its speciﬁc role in prostate cancer
screening and detection is yet to be determined [6]. It has
been found to have high negative predictive value com-
pared to other molecular-based screening tests and has
been identiﬁed as one of the most prostate cancer-speciﬁc
genes [6]. It was found to be absent in other tissues except
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DOI 10.1007/s00345-010-0623-6for kidney in which DD3 was expressed at an insigniﬁcant
level, however, signiﬁcantly upregulated in malignant
prostate tissue [7]. The accuracy of prostate cancer detec-
tion was found to be improved with the use of urine
DD3
PCA3 in patients with low PSA (\2.5 ng/ml) [8].
DD3
PCA3/PSA ratio on voided urine after prostate massage
showed a sensitivity of 61–67% and speciﬁcity of 80–83%
[6, 9]. Some studies have also shown an association with
pathologic variables including tumor volume and extra-
prostatic extension [10, 11]. Herein, we evaluate the role of
PCA3 in predicting pathologic features and compare PCA3
scores obtained from post-DRE voided and no-DRE cath-
eterized urines before and after radical prostatectomy.
Materials and methods
Between May 2007 and April 2008, 100 consecutive men
with biopsy-proven prostate cancer scheduled to undergo
robotic radical prostatectomy were enrolled in this IRB-
approved study after informed consent. Patient character-
istics are listed in Table 1. One patient discontinued the
study, and one patients’ pathology was sent for further
analysis and was not included; therefore, we analyzed a
total of 98 patients. Four urine samples were obtained from
each patient including post-DRE (V1), catheterized urine
without DRE (V2), and 10-day and 6-week postoperative
voided urines (V3 and V4) outlined as the following:
Visit 1 (pre-op)Digital Rectal Examination (DRE)—
voided urine collection
Visit 2 (time of prostatectomy): Catheterized initial urine
collection without DRE
Visit 3 (approximately 10 days post-prostatectomy):
Catheterized urine collection
Visit 4 (approximately 6 weeks post-prostatectomy):
Voided urine collection
A digital rectal examination consisting of 3 strokes per
prostatic lobe was performed by the treating physician.
After the urine specimens were obtained, they were stored
at 2–8C until analysis. The specimens were then subjected
to target capture, transcription-mediated ampliﬁcation, and
hybridization in order to quantify both PCA3 and PSA
mRNA. The ratio of PCA3 to PSA was used to calculate
the PCA3 score. All prostatectomy specimens were pro-
cessed and analyzed by a pathologist in the standard
fashion where the prostate was inked and suspicious areas
were examined for extraprostatic extension (EPE). Tumor
histology was graded using the Gleason grading system and
staged using the TNM Staging system [12]. Patient data are
described using appropriate descriptive statistics (mean and
SD for normally distributed variables, median and range
for non-normal variables, frequency and percent for cate-
gorical variables). The patients with informative rates
(mRNA detection) were investigated in univariate and
multivariate analysis for associations with pathologic fea-
tures (Table 2 and 3, respectively). Comparisons of the
associations of PCA3 scores and PSA levels with clinical
and pathologic stage, the presence of extraprostatic
extension, pathologic Gleason sum, and the presence of
perineural invasion were tested using a Mann–Whitney
non-parametric test. PSA density was calculated by using
the prostate weight obtained at prostatectomy. Sensitivity
and speciﬁcity, negative predictive values, and positive
predictive values were calculated to evaluate the ability of
the PCA3 score to identify patients with advanced patho-
logic stage, extraprostatic extension, perineural invasion
and Gleason sum[6 in comparison with PSA.
Results
The patient characteristics are presented in Table 1.
Informative rates (sufﬁcient mRNA for analysis) for V1,
Table 1 Patient characteristics
N Mean SD
Age 98 62.7 7.2
PSA 98 6.5 5.6
Prostate weight (gm) 96 51.7 19.3
Biopsy Gleason score 97 6.6 0.7
Pathologic Gleason score 89 6.8 0.6
N Percent
Biopsy Gleason score
6 or less 51 53.1
[6 46 47.9
Pathologic Gleason score
6 or less 29 29.9
[6 69 71.1
Pathologic stage
pT2 75 77.3
pT3a 16 16.5
pT3b 5 5.2
pT3c 0 0
pT4 1 1.0
Extraprostatic extension
No 77 78.6
Yes 21 21.4
Perineural invasion
No 24 24.5
Yes 74 75.5
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123V2, V3 and V4 were 91, 85, 0 and 2%, respectively.
Considering a value of 35 is a positive test, 73% of the V1
and V2 samples matched as positive values. PCA3 values
were collected pre-operatively (V1 and V2) and compared
to postoperative pathologic outcomes. There was no dif-
ference noted between those patients with informative and
non-informative tests regarding age, pre-operative PSA, or
pathologic grade and stage. Univariate analysis showed no
association with pathologic stage, the presence of extra-
prostatic extension, pathologic Gleason sum, or upgrading
from the biopsy Gleason sum (Table 2). The only adverse
pathologic feature that associated with voided urine PCA3
scores was the presence of perineural invasion
(P = 0.048). PSA alone was associated with higher path-
ologic stage (P = 0.034) (T2p vs. [T2p). In comparison
with PCA3, the addition of PSA density instead of the PSA
value alone increased associations with pathologic stage,
extraprostatic extension, and pathologic Gleason sum
(P = 0.0002, 0.0004, and 0.0003, respectively). Biopsy
Gleason sum was signiﬁcantly associated with all postop-
erative factors with all P values less than 0.02 (Table 2).
Gleason grading was upgraded at a rate of 26% in this
study but there were no pre-operative factors that could
predict this occurrence. In multivariate analysis, continu-
ous variables were used in quartiles to create categories for
observation for PSA, and PCA3 was not signiﬁcant for
perineural invasion (P = 0.071). No other variables were
statically signiﬁcant in multivariate analysis. PCA3 at V1
showed good speciﬁcity for identifying pathologic stage
(pT2 vs. CpT3), pathologic Gleason [6, upgrading,
extraprostatic extension, and perineural invasion using a
cutoff value of 35 (68, 77, 70, 67 and 82%, respectively
(Table 3). Sensitivity, however, was lower than expected
with values of 30, 35, 38, 26, and 36%, respectively. In
comparison with the PCA3 levels, PSA ([4 ng/dl) showed
excellent sensitivity (86, 81, 79, 86, and 76%) and had poor
speciﬁcity (25, 31, 23, 24, and 17%). PSAD [0.15 will
decrease sensitivity and increase speciﬁcity of PSA. Three
patients were taking 5-alpha reductase inhibiters during the
study. All three patients had informative specimens at V1
(4, 18, and 15); however, none of them had values greater
than 35. No patients showed an informative rate at the
postoperative visit (V3). At the 3-month follow-up (V4),
two patients had PCA3 informative rates of 21 and 70,
respectively.
Discussion
Three outcomes were sought in this study which include
the ability of PCA3 to be detected in catheterized urine,
predict pathologic aggressiveness and its role in cancer
recurrence. In the current study, there was sufﬁcient
mRNA isolated from urine to be able to measure PCA3
and PSA levels (informative rate) 91 and 85% for post-
DRE (V1) and catheterized V2 patients, respectively
(Table 3). These results are comparable to other studies
reporting informative rates ranging from 97 to 100% [9–
11]. Herein, we report for the ﬁrst time that PCA3
mRNA can be detected in catheterized urine without
DRE (V2) as the informative rate for this sample col-
lection protocol was 87%. This may be useful in patients
in which an adequate DRE may not be performed (i.e.,
patients with previous abdominoperineal resection) or
patients already undergoing catheterization (i.e., sterile
urine collection or the patient is on a clean intermittent
catheterization protocol).
We did not ﬁnd that PCA3 urine test to be a reliable
predictor of pathologic outcome prior to radical prosta-
tectomy. This ﬁnding is controversial as some studies have
reported an association of PCA3 score with higher risk for
adverse pathologic features, while others have not [9–11,
13, 14]. We evaluated PCA3 scores generated from both
post-DRE voided as well catheterized urine samples and
Table 2 Univariate analysis of pre-operative variables including PCA3 DRE and catheterized as well as PSA variables and the biopsy Gleason
compared to postoperative pathologic features including pathologic stage, extraprostatic extension, perineural invasion and pathologic Gleason
Pre-operative
variables
Postoperative/Pathologic variables Test for
association
Pathologic stage
(pT2 vs.[pT2)
Extraprostatic
extension
(yes vs. no)
Perineural
invasion
(yes vs. no)
Pathologic
Gleason
(6 vs.[6)
Upgrade (PGleason
[BGleason)
Patients P value Patients P value Patients P value Patients P value Patients P value
PCA3 voided 68 0.5502 89 0.3837 89 0.0479 89 0.1319 88 0.518 Mann–Whitney
PCA3 catheterized 88 0.5225 69 0.2899 69 0.1768 69 0.0254 69 0.608 Mann–Whitney
PSA 98 0.034 99 0.0822 99 0.4307 99 0.0503 98 0.864 Mann–Whitney
PSA density 97 0.0002 98 0.0004 98 0.3442 98 0.0003 97 0.8672 Mann–Whitney
Biopsy Gleason 97 0.0066 98 0.0117 98 0.0014 98 \0.001 Chi-square test
for trend
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123examined associations with pathologic stage, extraprostatic
extension, Gleason score, Gleason upgrading from biopsy
to prostatectomy specimens and perineural invasion,
showing only statistical signiﬁcance in perineural invasion
in univariate analysis (V1 P = 0.048) (Table 2). The sig-
niﬁcance of perineural invasion remains controversial;
however, it is assumed to be a feature of more aggressive
prostate cancers. Perineural invasion on the biopsy
specimen has shown that this can indicate upgrading of the
Gleason score and has predicted biochemical recurrence in
clinically localized prostate cancer [15–18]. In contrast,
perineural invasion on the prostate biopsy has not trans-
lated to long-term tumor-free survival [19]. Sensitivity and
speciﬁcity are not stastically signiﬁcant but is stated for
completeness of analysis. In this study, PCA3 offers no
additional information in predicting aggressiveness of
prostate cancer on postoperative pathology over PSA,
PSAD, and Biopsy Gleason sum [20, 21]. However, if the
PSA value is above 4, the addition of PCA3 may increase
the speciﬁcity (Table 3).
To investigate the potential role for PCA3 urine tests as
a means to monitor post-radical prostatectomy patients for
recurrence, we collected postoperative urine samples for
PCA3 analysis. Groskopf et. al. collected 3-month post-
prostatectomy voided urine on 21 patients for evaluation of
PCA3 score as a control group for the prostate speciﬁcity
on assay analysis and detected one patient with biochem-
ical recurrence [22]. Interestingly, the informative rates in
post-prostatectomy urine samples showed 0 and 2% for V3
and V4, respectively (Table 3). No patients had informa-
tive rates in the V3 samples; however, two patients had
informative PCA3 scores at V4 (scores = 70 and 21). One
of the patients PCA3 level was elevated prior to PSA
elevation. The proposed mechanisms are that after surgery,
the cancer cells may have gained better access to the uri-
nary system or the disease continued to advance as to
slough more cancer cells for detection likely in the region
of the bladder neck. The postoperative PCA3 informative
rate may be detectable prior to any large increases in PSA;
however, with only one patient in this study group, no
generalizations can be made at this time.
We acknowledge that we did not exclude patients taking
5-alpha reductase inhibitors. Three patients were taking 5-
alpha reductase inhibitors and still had informative rates;
although, only one had an informative rate above the 35
cutoff value. A recent study by van Gils et al. noted the
PCA3 score can be variable when using 5-alpha reductase
inhibitors such as dutasteride [23]. The medication may
lead to lower levels of PCA3 and PSA mRNAs; however,
the PCA3 scores were still attainable and further investi-
gation is needed. Moreover, the average PCA3 rates were
not positive (value of [35) in comparing the pathologic
outcomes. We are unsure of the exact mechanism in which
this study did not produce higher levels of PCA3 in patients
that had conﬁrmed prostate cancer when compared to other
studies. One potential confounder could be that not the
same physician performed all of the pre-operative digital
rectal examinations leading to technique variation. The
samples were collected, transported, and analyzed accord-
ing to prior studies and protocols set forth by Gen-Probe.
The power of this study is limited by sample size;
Table 3 Sensitivity, speciﬁcity, positive and negative predictive
values of the PCA3 score post-DRE void (V1), catheterized without
DRE (V2), and PSA to predict post-prostatectomy pathologic features
such as pathologic grade (pT2 vs. CpT3), cancer stage (II vs. CIII),
extracapsular extension, and perineural invasion
Sensitivity Speciﬁcity PPV NPV
Pathologic stage (pT2 vs.[pT2)
PCA3[35 0.30 0.68 0.21 0.77
PCA3[43 (Q4) 0.30 0.75 0.26 0.78
PSA[10 0.27 0.93 0.55 0.82
PSA[7 (Q4) 0.27 0.92 0.50 0.81
PSA[4 0.86 0.25 0.25 0.86
PSA density[0.15 (Q4) 0.55 0.82 0.46 0.86
Pathologic Gleason (6 vs.[6)
PCA3[35 0.35 0.77 0.79 0.33
PCA3[43 (Q4) 0.32 0.88 0.87 0.35
PSA[10 0.16 0.97 0.92 0.32
PSA[7 (Q4) 0.16 0.93 0.85 0.32
PSA[4 0.81 0.31 0.74 0.41
PSA Density[0.15 (Q4) 0.33 0.90 0.88 0.36
Gleason upgrade
(P Gleason[B Gleason)
PCA3[35 0.38 0.70 0.32 0.75
PCA3[43 (Q4) 0.33 0.77 0.35 0.75
PSA[10 0.07 0.86 0.17 0.69
PSA[7 (Q4) 0.07 0.84 0.15 0.68
PSA[4 0.79 0.23 0.30 0.73
PSA Density[0.15 (Q4) 0.21 0.72 0.24 0.68
Extraprostatic extension (no vs. yes)
PCA3[35 0.26 0.67 0.18 0.77
PCA3[43 (Q4) 0.26 0.74 0.22 0.79
PSA[10 0.24 0.91 0.42 0.82
PSA[7 (Q4) 0.24 0.90 0.38 0.81
PSA[4 0.86 0.24 0.23 0.86
PSA Density[0.15 (Q4) 0.52 0.81 0.42 0.86
Perineural invasion (no vs. yes)
PCA3[35 0.36 0.82 0.86 0.29
PCA3[43 (Q4) 0.31 0.91 0.91 0.30
PSA[10 0.13 0.92 0.83 0.26
PSA[7 (Q4) 0.13 0.88 0.77 0.24
PSA[4 0.76 0.17 0.74 0.18
PSA density[0.15 (Q4) 0.28 0.79 0.81 0.26
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123therefore, we caution extrapolation of the data. However,
this study does address uncharted areas of a relatively new
biochemical marker.
Conclusion
PCA 3 score can be collected via post-DRE voided urine
specimen as well as catheterized urine specimens and give
similar informative rates. In general, the PCA3 score did
not predict aggressive pathologic features of prostate can-
cer and does not seem to add additional value to prior to
treatment selection. Using follow-up data, a positive result
may cause concern for biochemical recurrence and allow
use of the PCA3 score postoperatively. Further long-term
studies are needed to conﬁrm prognostic and post-prosta-
tectomy surveillance information.
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